Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 is also expressed on Tregs; targeting CTLA-4 could theoretically lead to Treg cell dysfunction or depletion as has been demonstrated in mice (Simpson et al., 2013), though not all data support this notion in humans”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The lack of additive or synergistic therapeutic benefit of the combination of –CTLA-4 with peptide vaccination in the recent phase III clinical trial (Hodi et al., 2010) could at least be partially explained by a lack of vaccine-mediated impact on appropriate accessory cell populations.”
BackgroundInfluentialSelf-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“–CTLA-4 therapy has demonstrated significant antitumor activity in preclinical tumor models (Leach et al., 1996; van Elsas et al., 1999; Quezada et al., 2011) and in clinical trials as an immunotherapy for metastatic melanoma (Hodi et al., 2010; Robert et al., 2011).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 14×
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“…CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et al., 2008).”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
Background
Cited by
Items 201–300 of 1,000
Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
Sanmamed, M. F., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000061 · Cited by 178
“Recent studies indicate that one of themajor mechanisms of antitumor effect relatedwith anti– CTLA-4 monoclonal antibodies is based in depletion of T regulatory (Treg) cells.(13,14) It has been shown that CTLA-4 expression on Treg cells is critical for its expansion and activity.”
BackgroundTargeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
Qiao, J., Liu, Z., Dong, C., Luan, Y., Zhang, A., Moore, C., Fu, K., Peng, J., Wang, Y., Ren, Z., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.005 · Cited by 176
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
Basic Overview of Current Immunotherapy Approaches in Cancer
Velcheti, V., & Schalper, K. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156572 · Cited by 176
Ager, C. R., Reilley, M. J., Nicholas, C., Bartkowiak, T., Jaiswal, A. R., & Curran, M. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0049 · Cited by 180
“Combination efficacy correlated with globally enhanced ratios of CD8þ T cells to regulatory T cells (Treg), macrophages, and myeloid-derived suppressor cells, and downregulation of the M2 marker CD206 on tumor-associated macrophages.”
BackgroundInfluentialCytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Buchbinder, E., & Hodi, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80012 · Cited by 178
“CTLA-4–targeted antibodies deplete intratumoral Tregs by an unknown mechanism, possibly through antibody-dependent cell-mediated cytotoxicity (26, 27).”
BackgroundExhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Terranova-Barberio, M., Pawlowska, N., Dhawan, M., Moasser, M., Chien, A. J., Melisko, M. E., Rugo, H., Rahimi, R., Deal, T., Daud, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17414-y · Cited by 177
Eisinger, S., Sarhan, D., Boura, V. F., Ibarlucea-Benitez, I., Tyystjärvi, S., Oliynyk, G., Arsenian-Henriksson, M., Lane, D., Wikström, S. L., Kiessling, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015343117 · Cited by 173
“This would possibly work through CD8 + T cells, as melanoma have been used to develop checkpoint treatment for the clinic or, alternatively, by affecting CD4 + regulatory T cell number, as this has been shown to be affected by T cell targeting (33, 34).”
Self-citationIn situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille-Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 177
Chen, X., Song, X., Li, K., & Zhang, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00292 · Cited by 174
“In the MC38 mouse model, Dahan et al. reported that engagement of FcγRs reduced the anti-tumor activity of an anti-PD-1 antibody by eliminating CD8+ tumor-infiltrating lymphocytes (TILs) via ADCC in a FcγRI-dependent manner (9).”
BackgroundInfluentialDevelopment of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175
“Other studies have also reported a correlation between mutational load and response to immunotherapy (Snyder et al., 2014; Rizvi et al., 2015; Van Allen et al., 2015).”
BackgroundThe 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
Boustani, J., Grapin, M., Laurent, P.-A., Apétoh, L., & Mirjolet, C. (2019) · Cancers · doi:10.3390/cancers11060860 · Cited by 199
“immunosuppressive TME, while OX40 co-stimulatory molecules are upregulated only for a brief period after the antigen presentation induced by the radiation [86,87].”
BackgroundWhite, A. L., Chan, H. T. C., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.001 · Cited by 173
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 168
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Nimmerjahn, F., Gordan, S., & Lux, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.005 · Cited by 172
Nakagawa, H., Sido, J. M., Reyes, E. E., Kiers, V., Cantor, H., & Kim, H.-J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604765113 · Cited by 176
“For example, the antitumor activity of some anti–CTLA-4 Abs may reflect FcγR-dependent depletion of intratumoral Tregs in addition to targeting of Teff cells (17).”
BackgroundUnderstanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Sharma, M., Khong, H., Fa’ak, F., Bentebibel, S.-E., Janssen, L. M. E., Chesson, B. C., Creasy, C. A., Forget, M.-A., Kahn, L. M. S., Pazdrak, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14471-1 · Cited by 173
Wang, L., Amoozgar, Z., Huang, J., Saleh, M. H., Xing, D., Orsulic, S., & Goldberg, M. S. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0073 · Cited by 173
“GITR ligation enhances the infiltration and activity of effector T cells (33) and NK cells (22, 34) and generates effector T cells that are resistant to the immunosuppressive effects of Tregs (35).”
BackgroundInfluentialJones, G. W., Hill, D. G., & Jones, S. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00401 · Cited by 169
Foxp3 Post-translational Modifications and Treg Suppressive Activity
Deng, G., Song, X., Fujimoto, S., Piccirillo, C. A., Nagai, Y., & Greene, M. I. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02486 · Cited by 162
“Depleting intra-tumoral Tregs by treatment with immune checkpoint inhibitor monoclonal antibody against cytotoxic T lymphocyte–associated antigen 4 (anti-CTLA-4) promotes anti-tumor immune activity (61, 62).”
BackgroundLi, X., Su, X., Liu, R., Pan, Y., Fang, J., Cao, L., Feng, C., Shang, Q., Chen, Y., Shao, C., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01636-x · Cited by 160
Kumagai, S., Itahashi, K., & Nishikawa, H. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00870-6 · Cited by 186
“Moreover, Fc-mediated ADCC and/or antibody-dependent cellular phagocytosis (ADCP) triggered by anti-CTLA4 antibodies can selectively deplete T reg cells (owing to the high levels of CTLA4 on these cells), thereby relieving T reg cell-mediated suppression of cytotoxic T cells 101,102 .”
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
Xing, R., Gao, J., Cui, Q., & Wang, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783236 · Cited by 167
“apatinib + SHR1210 (42) I Advanced HCC PR rate 54.”
InfluentialToo Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
Ferris, R. L., Lu, B., & Kane, L. P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 173
“pletion of Treg (57, 58), despite two decades of study of CTLA-4 biology.”
BackgroundInfluentialStructural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
Ramagopal, U. A., Liu, W., Garrett-Thomson, S. C., Bonanno, J. B., Yan, Q., Srinivasan, M., Wong, S. C., Bell, A., Mankikar, S., Rangan, V. S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617941114 · Cited by 162
“In the case of ipilimumab, affinity-attenuated variants could be generated, which would exhibit selectivity for activated Treg cells present at tumor sites due to their higher expression levels of CTLA-4, compared with other activated T cells (20, 21).”
BackgroundCheckpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Dougan, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01547 · Cited by 170
Dahan, R., Barnhart, B. C., Li, F., Yamniuk, A. P., Korman, A. J., & Ravetch, J. V. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.001 · Cited by 165
“The requirements for FcgR interactions for the therapeutic activity of an increasing number of immunomodulatorymAbs (Bulliard et al., 2013, 2014; Dahan et al., 2015; Selby et al., 2013; Simpson et al., 2013) have emphasized the need to optimize these reagents by proper selection of the Fc domain.”
BackgroundSelf-citationTumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A., Flietner, E., Morrow, Z., Chaudhary, S. G., & Asimakopoulos, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 165
Page, D. B., Yuan, J., Redmond, D., Wen, Y. H., Durack, J. C., Emerson, R., Solomon, S., Dong, Z., Wong, P., Comstock, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0013 · Cited by 170
“CTLA-4 blockade is thought to decrease the threshold required for T-cell activation following exposure to antigen (16), increase the quality and duration of T-cell activation, and deplete suppressive T-regulatory cells within the tumor microenvironment (17).”
BackgroundInfluentialSelf-citationTissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A. S., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
Clinical landscape of macrophage-reprogramming cancer immunotherapies
Rannikko, J. H., & Hollmén, M. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02715-6 · Cited by 183
“While the ef fi cacy of several monoclonal antibodies depends on macrophage-mediated effector functions and activation of anti-tumour immunity, TAM-regulated immuno-suppression and T-cell exclusion remain major obstacles for effective immunotherapy [26, 207 – 209].”
Immune Checkpoints as a Target for Colorectal Cancer Treatment
Passardi, A., Canale, M., Valgiusti, M., & Ulivi, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061324 · Cited by 174
“5- to 2-fold increase in the proliferation of T cells, a 6-fold increase in the production of interleukin-2 [17,18] and the depletion of T regulatory lymphocytes in the tumor microenvironment through a macrophage-dependent process [18,19].”
BackgroundSynergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 161
Buchan, S. L., Dou, L., Remer, M., Booth, S. G., Dunn, S. N., Lai, C., Semmrich, M., Teige, I., Mårtensson, L., Penfold, C. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.014 · Cited by 160
Hannani, D., Vétizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaib, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.3 · Cited by 162
Self-citationThe role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Stewart, R., Hammond, S. A., Oberst, M., & Wilkinson, R. W. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0029-x · Cited by 157
“The depletion of T-regs was mediated predominantly by mouse FcγRIV, but was independent of NK cells, and considered likely to rely on the activity of intratumoral CD11b +macrophages [33].”
BackgroundMethodInfluentialPreserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
Liu, Y., & Zheng, P. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.003 · Cited by 162
Targeting tumor-associated macrophages as an antitumor strategy
Cheng, N., Bai, X., Shu, Y., Ahmad, O., & Shen, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114354 · Cited by 161
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.05.001 · Cited by 159
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 159
Wu, M.-J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 155
Inhibitory receptors as targets for cancer immunotherapy
Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 152
Size-Dependent Segregation Controls Macrophage Phagocytosis of Antibody-Opsonized Targets
Bakalar, M. H., Joffe, A. M., Schmid, E. M., Son, S., Podolski, M., & Fletcher, D. A. (2018) · Cell · doi:10.1016/j.cell.2018.05.059 · Cited by 160
Treg(s) in Cancer: Friends or Foe?
Wolf, D., Sopper, S., Pircher, A., Gastl, G., & Wolf, A. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25016 · Cited by 151
Immunosurveillance and therapy of multiple myeloma are CD226 dependent
Guillerey, C., Ferrari de Andrade, L., Vuckovic, S., Miles, K., Ngiow, S. F., Yong, M. C. R., Teng, M. W. L., Colonna, M., Ritchie, D. S., Chesi, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77181 · Cited by 152
“The depletion or neutralization of Tregs and the reactivation of NK and CD8 + effector lymphocytes upon CTX treatment may account for the immune-dependent action of CTX in our experiment.”
InfluentialNot All Immune Checkpoints Are Created Equal
De Sousa Linhares, A., Leitner, J., Grabmeier-Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 148
CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation
Chikuma, S. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_61 · Cited by 191
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Ishihara, J., Fukunaga, K., Ishihara, A., Larsson, H. M., Potin, L., Hosseinchi, P., Galliverti, G., Swartz, M. A., & Hubbell, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0401 · Cited by 157
“Higher doses (100 mg each per injection) of PlGF-2123–144–Abs using aCTLA4 clone 9H10, which induces Treg depletion (5), further suppressed tumor growth and extended survival (Fig.”
BackgroundAnti–CTLA-4 therapy requires an Fc domain for efficacy
Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L., Garforth, S., Fedorov, E., Fedorov, A. A., Bonanno, J. B., Le Gall, C., Crowley, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801524115 · Cited by 150
“on expression of the Fcγ receptor (FcγR), which may facilitate antibody-dependent cellular phagocytosis by tumor-associated macrophages (23, 24).”
BackgroundInfluentialCuende, J., Liénart, S., Dedobbeleer, O., van der Woning, B., De Boeck, G., Stockis, J., Huygens, C., Colau, D., Somja, J., Delvenne, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1983 · Cited by 155
“The activity of anti-CTLA4 mAbs in mice appears to depend in part on the ADCC-mediated depletion of tumorinfiltrating Tregs (47, 48).”
BackgroundTumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., & Milella, M. (2020) · Cancers · doi:10.3390/cancers12102870 · Cited by 172
The interplay of effector and regulatory T cells in cancer
Roychoudhuri, R., Eil, R. L., & Restifo, N. P. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.003 · Cited by 169
“However, CTLA-4 treatment results in increased Teff:Treg cell ratios within tumors [113 ,114,115] and its efficacy, in part, requires depletion of antibody-bound Treg cells by Fcg receptor–expressing macrophages within the tumor microenvironment [116,117].”
BackgroundSufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
Morrison, A. H., Diamond, M. S., Hay, C. A., Byrne, K. T., & Vonderheide, R. H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918971117 · Cited by 147
Ali, O. A., Lewin, S. A., Dranoff, G., & Mooney, D. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0126 · Cited by 146
“In contrast, a recent study demonstrated that combining anti–CTLA-4 with Gvax can deplete Treg numbers in a tumor microenvironment and this is dependent on the presence of tumor infiltrating, Fc receptor–expressing macrophages (14).”
ResultCD4 + CD25 + regulatory T cells in tumor immunity
Chen, X., Du, Y., Lin, X., Qian, Y., Zhou, T., & Huang, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.03.009 · Cited by 159
Magnuson, A. M., Kiner, E., Ergun, A., Park, J. S., Asinovski, N., Ortiz-Lopez, A., Kilcoyne, A., Paoluzzi-Tomada, E., Weissleder, R., Mathis, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810580115 · Cited by 144
Cancer Immunotherapy: Beyond Checkpoint Blockade
Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 164
“Indeed, the efficacy of anti-CTLA-4 therapy in murine models relies on the Fc domain, and several groups have reported that depletion of intratumoral Tregs may be the mechanism of action of CTLA-4–directed therapies (Bulliard et al. 2013, Marabelle et al. 2013, Simpson et al. 2013).”
BackgroundSingle‐cell analyses reveal suppressive tumor microenvironment of human colorectal cancer
Mei, Y., Xiao, W., Hu, H., Lu, G., Chen, L., Sun, Z., Lü, M., Ma, W., Jiang, T., Gao, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.422 · Cited by 171
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Kim, J.-H., Kim, B. S., & Lee, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e4 · Cited by 157
“Consequently, disrupting the function of the Fc portion of the Ab completely abrogated the anti-tumor activity of the anti-CTLA-4 mAb (79-82).”
BackgroundCancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 153
“It is also possible that anti CTLA-4 monoclonal antibodies cause regulatory T lymphocyte depletion in the tumor microenvironment [24, 25].”
BackgroundCellular and Molecular Mechanisms of Autoimmune Hepatitis
Webb, G. J., Hirschfield, G. M., Krawitt, E. L., & Gershwin, M. E. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043534 · Cited by 142
Song, H., Yang, P., Huang, P., Zhang, C., Kong, D., & Wang, W. (2019) · Theranostics · doi:10.7150/thno.30577 · Cited by 155
“Previous studies in mice have shown that anti-CTLA-4 monoclonal antibodies including ipilimumab, pembrolizumab, and tremelimumab, block the function of CTLA-4 and deplete intratumoral FOXP3+ regulatory T cells via an Fc-dependent mechanism [58-60].”
BackgroundCD28 co-stimulation in T-cell homeostasis: a recent perspective
Hünig, T., Beyersdorf, N., & Kerkau, T. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61647 · Cited by 194
Budhu, S., Schaer, D. A., Li, Y., Toledo-Crow, R., Panageas, K., Yang, X., Zhong, H., Houghton, A. N., Silverstein, S. C., Merghoub, T., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aak9702 · Cited by 143
“An attractive approach to this is using immunotherapies that specifically deplete Tregs from the tumor microenvironment without affecting Tregs systemically (3, 6, 31).”
BackgroundSelf-citationAntigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance
Muraoka, D., Seo, N., Hayashi, T., Tahara, Y., Fujii, K., Tawara, I., Miyahara, Y., Okamori, K., Yagita, H., Imoto, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97642 · Cited by 145
Self-citationThe B7:CD28 family and friends: Unraveling coinhibitory interactions
Burke, K. P., Chaudhri, A., Freeman, G. J., & Sharpe, A. H. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.013 · Cited by 155
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 163
“Using various transplantable models in knockout mice that lack one or more FcRs, tumor regression mediated by rituximab, anti-CTLA4, trastuzumab and other anti-ERBB2 antibodies is reversed [109-115].”
BackgroundImmunotherapies and Combination Strategies for Immuno-Oncology
Barbari, C., Fontaine, T., Parajuli, P., Lamichhane, N., Jakubski, S., Lamichhane, P., & Deshmukh, R. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145009 · Cited by 140
Lazăr, D. C., Avram, M. F., Romosan, I., Cornianu, M., Tăban, S. M., & Goldiș, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i32.3583 · Cited by 168
Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells
Ding, R., Yu, X., Hu, Z., Dong, Y., Huang, H., Zhang, Y., Han, Q., Ni, Z.-Y., Zhao, R., Ye, Y., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.019 · Cited by 157
Enhancement of T cell recruitment and infiltration into tumours
Oelkrug, C., & Ramage, J. M. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12382 · Cited by 139
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 149
Integrative biology of T cell activation
MALISSEN, B., Grégoire, C., Malissen, M., & Roncagalli, R. (2014) · Nature Immunology · doi:10.1038/ni.2959 · Cited by 143
OX40: Structure and function – What questions remain?
Willoughby, J. E., Griffiths, J., Tews, I., & Cragg, M. S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.01.006 · Cited by 144
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models
Campbell, J. R., McDonald, B., Mesko, P. B., Siemers, N. O., Singh, P. B., Selby, M., Sproul, T. W., Korman, A. J., Vlach, L. M., Houser, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3585 · Cited by 151
“Diphtheria toxin fused to IL2 (denileukin diftitox) failed to effectively reduce Treg numbers in patients with melanoma (8), and despite documented anti–CTLA4-mediated Treg depletion in mouse tumor models (9, 10), frank evidence for Treg depletion by ipilimumab or tremelimumab (anti-human CTLA4 antibodies) in human ca…”
BackgroundPai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141
“Ipilimumab is a humanized IgG1 antibody targeting CTLA-4, and one of its immunomodulatory mechanisms is engagement with FcgRIIIA to potentially antagonize or deplete regulatory T (Treg) cells (Simpson et al., 2013).”
de Coaña, Y. P., Wolodarski, M., Poschke, I., Yoshimoto, Y., Yang, Y., Nyström, M., Edbäck, U., Brage, S. E., Lundqvist, A., Masucci, G. V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15368 · Cited by 139
Localized CD47 blockade enhances immunotherapy for murine melanoma
Ingram, J. R., Blomberg, O. S., Sockolosky, J. T., Ali, L., Schmidt, F. I., Pishesha, N., Espinosa, C., Dougan, S. K., Garcia, K. C., Ploegh, H. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710776114 · Cited by 138
“Although local delivery of A4 was effective, GVAX-αCTLA-4 in combination with A4Fc caused considerable toxicity (Fig.”
BackgroundInfluentialTumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Pai, C.-C. S., Simons, D. M., Lu, X., Evans, M., Wei, J., Wang, Y.-H., Chen, M., Huang, J., Park, C., Chang, A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123391 · Cited by 135
“3 5 8 jci.org Volume 129 Number 1 January 2019 shown by the 9H10 and 24H2 clones, which are better at depleting Tregs through ADCC compared with the UC-10 clone of antiCTLA4 Ab (44).”
BackgroundResultInfluentialCurrent Targeted Therapy for Metastatic Colorectal Cancer
Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 150
“Inhibition of CTLA-4 binding to these ligands results in the reactivation and proliferation of T cells and decreases immunosuppressive Tregs, leading to increased activation of the immune system in the tumor microenvironment [123].”
BackgroundDiLillo, D. J., & Ravetch, J. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0120 · Cited by 132
“As with the agonistic mAbs above, it was unexpectedly found that engagement of activating FcgRs is required for optimal antitumor activity in preclinical models using anti–CTLA-4 (44, 45), anti-GITR (46), and anti-OX40 (47) mAbs.”
BackgroundSelf-citationMechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 130
Hannani, D., Vétizou, M., Enot, D. P., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaïb, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.28 · Cited by 135
Self-citationImmunotherapy comes of age: Immune aging & checkpoint inhibitors
Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.02.001 · Cited by 133
Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 145
Orchestrating immune check-point blockade for cancer immunotherapy in combinations
Perez‐Gracia, J. L., Labiano, S., Rodriguez-Ruiz, M. E., Sanmamed, M. F., & Melero, I. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.002 · Cited by 139
“Very recently it has been shown that anti-CTLA-4 mAb deplete Treg cells via macrophage-mediated ADCC as elicited by FcgRIV but only in the tumor microenvironment [72].”
Rashidian, M., LaFleur, M. W., Verschoor, V. L., Dongre, A., Zhang, Y., Nguyen, T. H., Kolifrath, S., Aref, A. R., Lau, C. J., Paweletz, C. P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905005116 · Cited by 129
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
Cleary, K. L. S., Chan, H. T. C., James, S., Glennie, M. J., & Cragg, M. S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601473 · Cited by 139
(2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2165 · Cited by 127
“However, WR did not compromise the upregulation of PD-L1–caused type 2 IFN (produced by effector T cells in the TME, not shown).”
BackgroundInfluentialMahne, A. E., Mauze, S., Joyce-Shaikh, B., Xia, J., Bowman, E. P., Beebe, A. M., Cua, D. J., & Jain, R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0797 · Cited by 121
Kong, Y.-C. M., & Flynn, J. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00206 · Cited by 124
“Although in murine melanoma studies Fc-dependent ADCC-like depletion of Tregs was demonstrable upon anti-CTLA treatment (43), the frequent detection of intratumoral iTregs in the human suggests that this kind of depletion might be an adjunct to improved clinical benefit.”
BackgroundTumor-associated macrophages and anti-tumor therapies: complex links
Belgiovine, C., D’Incalci, M., Allavena, P., & Frapolli, R. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2166-5 · Cited by 137
Influence of immunoglobulin isotype on therapeutic antibody function
Beers, S. A., Glennie, M. J., & White, A. L. (2016) · Blood · doi:10.1182/blood-2015-09-625343 · Cited by 119
CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
Yshii, L., Gebauer, C., Pignolet, B., Mauré, E., Queriault, C., Pierau, M., Saito, H., 昇, 鈴., Brunner-Weinzierl, M. C., Bauer, J., et al. (2016) · Brain · doi:10.1093/brain/aww225 · Cited by 127
“Downloaded from https://academic.oup.com/brain/article-abstract/139/11/2923/2422132 by guest on 31 December 2017 depletes Treg cells selectively from tumour via Fc recep- tor-expressing local macrophages, while the absolute numbers of effector T cells are increased (Simpson et al., 2013).”
MethodInflammation as target in cancer therapy
Marelli, G., Sica, A., Vannucci, L. E., & Allavena, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.007 · Cited by 133
A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells
Hou, T. Z., Qureshi, O. S., Wang, C. J., Baker, J., Young, S. P., Walker, L. S. K., & Sansom, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401876 · Cited by 118
“Recent evidence that Treg provide a key mechanism of anti–CTLA-4 efficacy is supported by the demonstration in tumor therapy that effectiveness required Treg depletion dependent on the Fc region of the anti–CTLA-4 Ab (52).”
BackgroundDu, X., Liu, M., Su, J., Zhang, P., Tang, F., Ye, P., Devenport, M., Wang, X., Zhang, Y., Liu, Y., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0012-z · Cited by 123
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Furness, A. J. S., Vargas, F. A., Peggs, K. S., & Quezada, S. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.002 · Cited by 125
Self-citation
Metadata
- Authors
- Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., & Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Rockefeller University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 3
- University College London (GB)
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK 6
- Department of Immunology, Juntendo University School of Medicine, 113-8421 Tokyo, Japan 5
- Corresponding author
- Allison, James P.
- Quezada, Sergio A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-07-29
- Volume
- 210
- Issue
- 9
- Pages
- 1695-1710
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3754863
- OpenAlex
- W2121080857
- Cited by
- 1,472
- References
- 60
- Citations by year
- 2026: 66 · 2025: 79 · 2024: 97 · 2023: 89 · 2022: 112 · 2021: 140 · 2020: 158 · 2019: 125 · 2018: 122 · 2017: 126 · 2016: 121 · 2015: 135 · 2014: 85 · 2013: 15
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CTLA-4, regulatory T cells, melanoma, Fc gamma receptor, tumor-infiltrating macrophages, T cell depletion, tumor microenvironment, cancer immunotherapy, metastatic melanoma
- MeSH terms
- Animals, Cell Membrane, Clone Cells, Lymph Nodes, Lymphocyte Depletion, Melanoma, Mice, Inbred C57BL, Phagocytes, Signal Transduction, CD4 Antigens, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Receptors, IgG, CD8-Positive T-Lymphocytes, Lymphocyte Count, Antibodies, Blocking, CD11b Antigen, T-Lymphocytes, Regulatory, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein, Tumor Microenvironment, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.